You are here: Industry Insights > Bristol-Myers Squibb

News List

BMS(nivolumab) now the first and only FDA-approved PD-1 inhibitor of every four-week dosing worldpharmanews
March 12, 2018
Bristol-Myers Squibb Company (NYSE:BMY) announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) updating the Opdivo ® (nivolumab) dosing schedule to include 480 mg infused every four weeks (Q4
Immuno-Oncology Sector Deals Dominate 2017 Life Sciences Deal of the Year Awards biospace
March 08, 2018
The rapidly innovating immuno-oncology sector is transforming the cancer treatment landscape, and the results of the Clarivate Cortellis 2017 “Deal of the Year” awards bear that out
FDA Expands Bristol-Myers Squibb’s Opdivo Dosing Schedule biospace
March 07, 2018
The U.S. Food and Drug Administration (FDA) expanded the dosing schedule for Bristol-Myers Squibb Company’s Opdivo (nivolumab)
Bristol-Myers Squibb to Take Part in Cowen and Company 38th Annual Global Health Care Conference biospace
March 06, 2018
Bristol-Myers Squibb Company (NYSE:BMY) will participate in the Cowen and Company 38th Annual Global Health Care Conference on Monday, March 12, 2018, in Boston
Bristol-Myers Squibb beats Street revenue, EPS estimates in Q4 as Eliquis surges fiercepharma
February 06, 2018
The same day Bristol-Myers Squibb reported a closely watched trial win for cancer combo Opdivo-plus-Yervoy in certain lung cancer patients, the drugmaker announced 2017 results, beating expectations with Opdivo and anticoagulant Eliquis.
Bristol-Myers Squibb's Yervoy scores EU approval in paediatric melanoma pharmafile
January 24, 2018
Bristol-Myers Squibb has revealed that its immunotherapy Yervoy has received an expanded indication from the European Commission, approving the drug for use in the European Union in the treatment of advanced melanoma in paediatric patients 12 years of ag
Bristol-Myers Squibb (BMY) Downgraded by Vetr to “Hold” americanbankingnews
December 26, 2017
Bristol-Myers Squibb (NYSE:BMY) was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating in a note issued to investors on Friday.
3 Immuno-oncology therapeutics expected to Blast Off in 2018 biospace
December 25, 2017
Immuno-oncology therapeutics have revolutionized certain types of cancer treatments.
Bristol-Myers Squibb to Announce Results for Fourth Quarter 2017 on February 5th biospace
December 20, 2017
Bristol-Myers Squibb (NYSE: BMY) will release fourth quarter results for 2017 on Monday, February 5, 2018.
BMS and Pfizer Alliance urge people to tune in to Afib to reduce Stroke Risk worldpharmanews
December 06, 2017
Bristol-Myers Squibb and Pfizer Alliance, National Stroke Association and iHeartMedia today released "Adjusting AFib to Document Stroke Risk"

Previous page 1 2 3 4 5 6 7 8 9 10 Next page